Join us for a webinar featuring leading experts in antimicrobial drug development, who will share their insights on in vitro standardisation.
Time-Kill Curve (TKC) evaluations and in vitro modelling simulations are essential steps in the study of an antimicrobial’s pharmacodynamic characteristics. They are increasingly used to advance candidates through a drug development platform. Whilst there are formal standards for static evaluations, such as minimum inhibitory concentration (MIC) assays, ensuring robust, reproducible, and high-quality data, surprisingly, this is not the case for dynamic systems. There remains concern that different testing centres and methodologies may yield significantly different results, which could affect the understanding of bacterial and dose-response interactions. During the webinar, Gram-negative-Antibiotics NOW (GNA-NOW) experts will discuss the evaluation of TKC and in vitro model comparison studies to date.

At the end, webinar attendees can participate in an exclusive Q&A session!

Time:
9 December, 15:00 – 16:30 CET

Speakers:
Marie Attwood
– Head Research Scientist at the Southmead Hospital, North Bristol NHS Trust

Professor Alasdair MacGowan
– Consultant in Infection Research at North Bristol NHS Trust
– Professor of Antimicrobial Therapeutics at the University of Bristol

Moderator:
Frederik Deroose
– CEO, Connecting Pharma

Register for the webinar by clicking this link or pasting https://forms.biocom.de/index.php/596796?lang=en in the browser.

Don’t hesitate to contact Fredeik Deroose (COMBINE) if you have any questions.